国产一区二区三区视频精品-国产一区二区三区视频在线观看-国产一区二区三区四区五区-国产一区二区三区四区五区精品-国产一区二区三区无码免费-国产一区二区三区在线

美國Bioscan
美國的Bioscan公司成立于1980年，為生命科學研究領域帶來了大批的分析儀器。在放射性同位素標記成分檢測研究領域，除了有HPLC和TLC檢測儀和掃描儀外，發(fā)光監(jiān)測和γ計數(shù)也可以在桌上型的計數(shù)器內完成。
Bioscan is a leading developer of advanced instrumentation for the detection, synthesis, and imaging of Radiolabeled Compounds used in these 4 areas…
Life Science Research
Molecular Imaging
Pharmaceutical Development
Nuclear Medicine
History:

Founded in 1980, Bioscan has supplied customers with unique research productivity tools for more than 25 years.

Thousands of customers worldwide--in universities, research hospitals, government laboratories, and pharmaceutical companies--use Bioscan products for basic biomedical research…and for the production of radiopharmaceuticals.

With the introduction of its NanoSPECT/CT in vivo imaging system in 2006, Bioscan sets a new standard in the field of molecular imaging of animal models for biological & disease research.

Mission Statement:

Bioscan’s mission is to facilitate early disease diagnosis--and accelerate drug discovery--by providing innovative technologies for bio-tracer chemistry and preclinical imaging. Our goal is to continue to provide researchers with reliable, flexible, and easy-to-use instrumentation that offers state-of-the-art performance capabilities.

SPECT and PET Imaging Systems from BIOSCAN
BIOSCAN is a leading provider of SPECT (Single Photon Emission Computed Tomography) and PET (Positron Emission Tomography) imaging systems for preclinical applications. Our tools enable researchers, pharmaceutical and biotech organizations to improve their drug development research using in vivo animal models.

Preclinical imaging uses molecular biomarkers in small animals to conduct in vivo methods by providing more relevant biological data, more consistency, as well as reduced cost and complexity. This unique imaging acuity also makes it possible to translate research results from mouse models of human diseases to human clinical trials – driving increased speed to market for drugs.

Improve Screening of Drug Pipeline Candidates
Our patented technology improves screening of drug pipeline candidates over classic in vitro methods by providing more relevant biological data, more consistency, as well as reduced cost and complexity. This unique imaging acuity also makes it possible to translate research results from mouse models of human diseases to human clinical trials – driving increased speed to market for drugs.

Innovative Instruments for Radioisotope Detection and Analysis
BIOSCAN is also a supplier of innovative instruments for radioisotope detection and analysis in life science, pharmaceutical and nuclear medicine research applications. As an expansion of its involvement in nuclear medicine, BIOSCAN now provides a variety of automated synthesis modules for the production of PET (F-18 & C-11) radiopharmaceuticals. Our analytical instruments provide solutions to both chemical purity and quality control in many applications involving radio-TLC, radio-HPLC, liquid scintillation counting, microplate detection and others.